These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27546350)

  • 1. Development of a Rational Design Space for Optimizing Mixing Conditions for Formation of Adhesive Mixtures for Dry-Powder Inhaler Formulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    J Pharm Sci; 2017 Jan; 106(1):129-139. PubMed ID: 27546350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic investigation of mixing and segregation of ordered mixtures: experiments and numerical simulations.
    Sarkar S; Minatovicz B; Thalberg K; Chaudhuri B
    Drug Dev Ind Pharm; 2017 Oct; 43(10):1677-1685. PubMed ID: 28574733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of high shear mixing on ternary dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2017 Dec; 534(1-2):242-250. PubMed ID: 29051120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linking carrier morphology to the powder mechanics of adhesive mixtures for dry powder inhalers via a blend-state model.
    Rudén J; Frenning G; Bramer T; Thalberg K; An J; Alderborn G
    Int J Pharm; 2019 Apr; 561():148-160. PubMed ID: 30825556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between surface coverage ratio and powder mechanics of binary adhesive mixtures for dry powder inhalers.
    Rudén J; Frenning G; Bramer T; Thalberg K; Alderborn G
    Int J Pharm; 2018 Apr; 541(1-2):143-156. PubMed ID: 29454905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces.
    Zhou QT; Morton DA
    Adv Drug Deliv Rev; 2012 Mar; 64(3):275-84. PubMed ID: 21782866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2018 Jan; 535(1-2):59-67. PubMed ID: 29100914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO; Khalafallah NM; Molokhia AM; Elsayed MMA
    AAPS PharmSciTech; 2018 Feb; 19(2):912-922. PubMed ID: 29063377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):898-909. PubMed ID: 24756910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
    Kinnunen H; Hebbink G; Peters H; Shur J; Price R
    AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Role of Fine Excipient Materials in Carrier-Based Dry Powder Inhalation Mixtures: Effect on Deagglomeration of Drug Particles During Mixing Revealed.
    Shalash AO; Elsayed MMA
    AAPS PharmSciTech; 2017 Nov; 18(8):2862-2870. PubMed ID: 28421352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling the performance of adhesive mixtures for inhalation using mixing energy.
    Thalberg K; Papathanasiou F; Fransson M; Nicholas M
    Int J Pharm; 2021 Jan; 592():120055. PubMed ID: 33176199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K; Åslund S; Skogevall M; Andersson P
    Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.